Cyclodextrin Reduces Cholesterol Crystal–Induced Inflammation by Modulating Complement Activation

Cholesterol Crystals Activate the Lectin Complement Pathway via Ficolin-2 and Mannose-Binding Lectin: Implications for the Progression of Atherosclerosis

(2016) Katrine Pilely et al.   JOURNAL OF IMMUNOLOGY

Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases—C3 or C5 emerge together with CD14 as promising targets

(2016) Andreas Barratt-Due et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming

(2016) Sebastian Zimmer et al.   Science Translational Medicine

Complementary Roles of the Classical and Lectin Complement Pathways in the Defense against Aspergillus fumigatus

(2016) Anne Rosbjerg et al.   Frontiers in Immunology

Statin Intolerance

(2015) David H. Fitchett et al.   CIRCULATION

Is the Complement Activation Product C3a a Proinflammatory Molecule? Re-evaluating the Evidence and the Myth

(2015) Liam G. Coulthard et al.   JOURNAL OF IMMUNOLOGY

Role of complement in IgA nephropathy

(2015) Mohamed R. Daha et al.   JOURNAL OF NEPHROLOGY

How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease

(2015) David M Diamond et al.   Expert Review of Clinical Pharmacology

Cholesterol Crystals Induce Complement-Dependent Inflammasome Activation and Cytokine Release

(2014) E. O. Samstad et al.   JOURNAL OF IMMUNOLOGY

Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events

(2014) S. Matthijs Boekholdt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A vital role for complement in heart disease

(2014) Knut T. Lappegård et al.   MOLECULAR IMMUNOLOGY

Statin Therapy for Primary Prevention of Cardiovascular Disease

(2013) Fiona C. Taylor et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Targeting Cholesterol Crystal-Induced Inflammation for the Secondary Prevention of Cardiovascular Disease

(2013) Stefan M. Nidorf et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

An international serum standard for application in assays to detect human complement activation products

(2013) Grethe Bergseth et al.   MOLECULAR IMMUNOLOGY

Complement and atherosclerosis—united to the point of no return?

(2012) Michael Torzewski et al.   CLINICAL BIOCHEMISTRY

New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties

(2012) Hongchang Qu et al.   IMMUNOBIOLOGY

Cyclodextrin mediates rapid changes in lipid balance inNpc1−/−mice without carrying cholesterol through the bloodstream

(2012) Anna M. Taylor et al.   JOURNAL OF LIPID RESEARCH

Effects of cyclodextrin in two patients with Niemann–Pick Type C disease

(2012) Muneaki Matsuo et al.   MOLECULAR GENETICS AND METABOLISM

Differential Expression of NLRP3 among Hematopoietic Cells

(2011) G. Guarda et al.   JOURNAL OF IMMUNOLOGY

Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation

(2010) George S. Abela   Journal of Clinical Lipidology

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

(2010) Peter Duewell et al.   NATURE

Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation

(2010) Kristiina Rajamäki et al.   PLoS One

Cyclodextrins

(2008) Valentino J. Stella et al.   TOXICOLOGIC PATHOLOGY